Biotech Values

[jq1234]

FDA panel says anti-NGF pain drug trials should continue


(Reuters) - A panel of advisers on Monday voted unanimously that companies such as Pfizer Inc and Regeneron Pharmaceuticals Inc should be allowed to continue testing a type of painkiller that helps people but can destroy joints.

The advisers to the U.S. Food and Drug Administration voted 21-0 that the agency should lift its hold on clinical trials of the drugs, from the class of anti-nerve growth factors.

http://www.reuters.com/article/2012/03/12/us-fda-pain-idUSBRE82B1DG20120312?feedType=RSS&feedName=healthNews&utm_source=dlvr.it&utm_medium=twitter&dlvrit=309303